A carregar...
Efficacy and Safety of Pembrolizumab for Gemcitabine/Cisplatin-Refractory Biliary Tract Cancer: A Multicenter Retrospective Study
Pembrolizumab, an anti-programmed cell death (PD)-1 monoclonal antibody, is an anticancer agent showing substantial benefit in lung cancer and melanoma treatment. Biliary tract cancer (BTC) has been shown to respond to pembrolizumab; however, no credible data of such treatment outcomes exist. Theref...
Na minha lista:
| Publicado no: | J Clin Med |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7355970/ https://ncbi.nlm.nih.gov/pubmed/32517311 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9061769 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|